期刊文献+

DM/PM中核因子-κВ的表达及作用机制探讨

The expression and role of NF-κВ in DM/PM
暂未订购
导出
摘要 目的通过研究NF-κВ在DM/PM患者骨骼肌的表达情况,以及DM患者血清体外对脐静脉内皮细胞(HUVEC)NF-κВ表达的影响,初步探讨NF-κВ在DM/PM中的相关作用的机制。方法采用免疫组织化法对25例DM/PM患者骨骼肌中的NF-κВ(P65)进行检测,取16例DM患者治疗前和6例治疗后的血清加入体外培养的HUVEC中,用细胞免疫组织化法检测HUVEC株NF-κВ(P65)的表达。结果 NF-κВ(P65)在DM/PM患者骨骼肌内的微血管内皮细胞和肌纤维中表达上调,与正常对照组相比差异有显著性(P<0.05),正常对照组无表达;DM患者治疗前血清体外作用HUVEC 6h后,(11.126±1.920)%细胞表达阳性,24h后细胞的阳性率上升到(17.048±1.140)%,差异有统计学意义(P<0.01);治疗后血清对脐静脉内皮细胞(HUVEC)的NF-KB(P65)阳性表达率分别为(6.797±0.609)%(6h)和(11.273±0.643)%(24h),二者均低于相应的治疗前表达率(P<0.01)。结论 NF-κВ在DM/PM肌肉微血管肌纤维的炎症性反应过程中发挥重要作用,其在DM患者血清中可能有激活NF-κВ的成分。 Objective To investigate the role of NF-κB in the pathogenesis of DM / PM. Methods The expression of NF-κB(p65) in the skeletal muscle of 25 cases with DM/PM was detected with the immunohistochemistry staining methos. The HUVEC were treated with serum of the 16 pre-treatment and 6 post-treatment patients with DM in vitro, and the expression of NF-KB (p65)in HUVEC was also detected. Results Compared with the normal control, the expression of NF-κB(p65)in the skeletal muscle microvascular endothe- lial cells and muscle fibers of patients with DM/PM was increased significantly( P〈0.05 ). It was no expression in normal control. When the HUVEC were treated with the serum of pre-treated patients with DM for 6 hours, the positive rate was (11. 126±1. 920)% , after 24 hours was ( 17. 048± 1. 140) %. There was significant difference ( P〈0. 001 ). The expression of NF-KB ( p65 ) in HUVEC treated with the serum of the post-treated patients with DM for 6 hours and 24 hours was (6. 797 ±0. 609 ) % and ( 11. 273±0. 643 ) % separately. Conclusion NF-κB play an important role in the muscle microvascular inflammatory response of the muscle fibers of patients with DM / PM. There may have the ingredients to activate NF-κB in the serum of patients with DM.
出处 《皮肤病与性病》 2013年第4期189-192,共4页 Dermatology and Venereology
关键词 皮肌炎 多肌炎 核因子-κВ 脐静脉内皮细胞 Dermatomvositis Polvmvositis : NF- κB : HUVEC
  • 相关文献

参考文献11

  • 1Creus KK, De Paepe B, De Bleecker JL. Idiopathic inflammatory my- opathies and the classical NF-kappaB complex: current insights and implications for therapy [ J ]. Autoimmun Rev, 2009, 8 (7) : 627 -631.
  • 2王国春.对特发性炎性肌病诊断标准的新认识[J].中华风湿病学杂志,2008,12(4):219-221. 被引量:7
  • 3王海云,王国林.氯胺酮对脂多糖诱导下人脐静脉内皮细胞活化的影响[J].中华麻醉学杂志,2004,24(5):357-360. 被引量:9
  • 4Macaione V, Aguennouz M, Rodolico C, et at. RAGE-NF-kappaB pathway activation in response to oxidative stress in facioscapulohumer- al muscular dystrophy [J]. Acta Neurol Scand, 2007, 115(2) : 115 -121.
  • 5Mourkioti F, RosenthaL N. NF-KB signaling in skeletal muscle: pros- pects for intervention in muscle diseases [ J]. J Mol Med, 2008, 86 (7) : 747-759.
  • 6Acharyya S, Villaha SA, Bakkar N, et at. Interplay of IKK/NF-kap- paB signaling in macrophages and myofibers promotes muscle degener- ation in Duchenne muscular dystrophy [ J]. J Clin Invest, 2007, 117 (4) : 889-901.
  • 7Liprandi A, Bartoli C, Figarella-Branger D, et at. Local expression of monocyte ehemoattractant protein-1 ( MCP-1 ) in idiopathic inflam- matory myopathies [Jl. Acta Neuropathol, 1999, 97(6) : 642-648.
  • 8De Bleeeker JL, De Paepe B, Vanwalleghem IE, et at. Differential expression of chemokines in inflammatory myopathie [ J ]. Neurology, 2002, 58(12) : 1779-1785.
  • 9Messina S, Vita GL, Aquennouz M, et at. Activation of NF-kappaB pathway in Duchenne muscular dystrophy:relation to age[J]. Acta Myol, 2011, 30(1): 16-23.
  • 10Haslbeck KM, Friess U, Schleicher ED, et al. The RAGE pathway in inflammatory myopathies and limb girdle muscular dystrophy [J]. Acta Neuropathol, 2005, 110 (3) : 247-254.

二级参考文献24

  • 1Dalakas MC, Hohlfeld R. Polymyositis and dermatomyositis.Lancet, 2003, 362: 971-982.
  • 2Dalakas MC. Autoimmune muscular pathologies. Neurol Sci, 2005, 26: 7-8.
  • 3Needham M, Mastaglia F. Inclusion body myositis: current pathogenetic concepts and diagnostic and therapeutic approaches. Lancet Neurol, 2007, 6:620-631.
  • 4Bohan A, Peter J. Polymyositis and dermatomyositis (first of two parts). N Engl J Med, 1975, 292: 344-347.
  • 5Bohan A, Peter J. Polymyositis and dermatomyositis (second of two parts). N Engl J Med, 1975, 292: 403-407.
  • 6Griggs RC, Askanas V, DiMauro S, et al. Inclusion body myositis and myopathies. Ann Neurol, 1995, 38: 705-713.
  • 7Van der Meulen MFG, Bronner IM, Hoogendijk JE, et al. Polymyositis: an overdiagnosed entity. Neurology, 2003, 61: 316- 321.
  • 8Hoogendijk J, Amato A, Lecky B, et al. 119th ENMC international workshop: the design in adult idiopathic inflammatory myopathies, with exception of inclusion body myositis. Neuromuscul Disord, 2004, 14:337-345.
  • 9Targoff l, Miller F, Medsger T, et al. Classification criteria for the idiopathic inflammatory myopathies. Curr Opin Rheumatol, 1997, 9: 527-535.
  • 10Targoff IN. Myositis specific autoantibodies. Curr Rheumatol Rep, 2006, 8: 196-203.

共引文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部